Emily I Chen

Title: Inventor Profile: Emily I Chen

Introduction

Emily I Chen is an innovative inventor based in Encinitas, California, who has made significant contributions to the field of biomedical research. With a total of two patents to her name, her work primarily revolves around the development of selective substrates for matrix metalloproteinases, showcasing her expertise in this vital area of study.

Latest Patents

Emily's latest patents include groundbreaking inventions that provide isolated MMP-2, MMP-9, and MT1-MMP selective substrate polypeptides or functional peptidomimetics. These selective substrate polypeptides exhibit specific sequences where MMP-2 selective substrate polypeptides contain SEQ ID NOS:1-27, MMP-9 selective substrate polypeptides have SEQ ID NOS:28-35, and MT1-MMP selective substrate polypeptides are identified by SEQ ID NOS:36-40. Moreover, her inventions offer methods for preferentially directing a moiety to sites of MMP-2, MMP-9, and MT1-MMP activity, enhancing therapeutic approaches by linking isolated polypeptides to specific moieties.

Career Highlights

Emily has worked at prominent institutions, including the Burnham Institute for Medical Research and the Sanford Burnham Medical Research Institute. These positions have allowed her to advance her research and collaborate with some of the leading scientists in her field, reflecting her commitment to innovation and the betterment of medical science.

Collaborations

Throughout her career, Emily has worked alongside notable colleagues such as Jeffrey W Smith and Steven J Kridel. These collaborations have likely enriched her research endeavors, providing varied perspectives and insights that contribute to the development of her innovative solutions in matrix metalloproteinase research.

Conclusion

Emily I Chen is a remarkable inventor whose contributions to the field of biomedical research highlight the importance of innovation in medical science. Her patents on selective substrates for matrix metalloproteinases pave the way for improved therapeutic strategies, solidifying her reputation as a leading innovator in her domain.